文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 基础医学 > In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic
侵权投诉

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model a pre-clinical study

To determine the effect on established disease, mice (n=5 per group) were treated with either 1mg/kg Fig. 4. p38 MAPK inhibition reduces established chronic CIA.

or 10mg/kg GSK678361 daily from day 1 of arthritis (either 1mg/kg or 10mg/kg GSK678361 daily from day 14 of arthritis (a), or with vehicle from day 1 followed by with either vehicle alone for the full period of the study or left untreated. Clinical score was assessed b). Further groups were treated over a 4 week period, and data are expressed as either mean ± SEM (a, b) or as area-under-curve (Statistical analyses were carried out by 1-way ANOVA: *p<0.05, ***p<0.001.

versus vehicle-treated mice either (a, b) by 2-way ANOVA or (c) c). Area-under-curve analysis con rmed a signi cant with ity reduction 2.13±0.04mm; data not shown).

vehicle alone (untreated animals relative in GW856553X-treated in disease sever-Histological 2b). to vehicle-treated animals, porting tional Such joint evidence, analysis showing provided sup-in GW856553X-treated in ammation and mission this comparison analysis allowed mice for addi-(Fig. complex model, of disease in which severity re-evident mice, destruction reduced which was in ferent (Fig. A days and relapse for individual occurred on dif-interphalangeal joints were mirrored for 3a-e). at all The doses data of shown GW856553X for distal thickness was measured. On day 29 of similar effect was seen when animals. paw the arthritis, paw thickness measurements geal, rst metatarsal joint and tibia-tar-other joints (proximal interphalan-were sal joints) and are summarised in Table and I and Fig. 3f.

with 1.88±0.02mm 1.91±0.02mm, 1.96±0.03mm, The effectiveness of p38 MAPK inhi-GW856553X 0.8mg/kg, for mice treated bition with 2.18±0.04mm for animals treated respectively, 4mg/kg and compared 20mg/kg using in chronic CIA was con rmed inhibitor, an namely alternative GSK678361, p38 MAPK which

181

has GW856553X comparable shown). GSK678361 was administered in acute in vivoCIA ef cacy (data not to at either 1mg/kg or 10mg/kg daily ei-ther from day 1 of arthritis, and dose-dependently model (Fig. 4a).

reduced arthritis in this Effect of p38 MAPK inhibitor on established chronic CIA

We further assessed the effect on estab-lished chronic CIA using GSK678361, which was administered at either 1mg/kg or 10mg/kg daily from day 14 of ar-thritis hicle). Drug-treated animals were com-(with prior treatment using ve-pared mice receiving vehicle for the full peri-to untreated arthritic mice, or od of the study (4 weeks). Delaying the start of treatment with GSK678361 to day 14 of arthritis reduced established disease ing GSK678361 treatment (day 13), all (Fig. 4b). Prior to commenc-groups able. However, by day 23 of arthritis, of animals were indistinguish-there receiving was comparable with animals who had re-GSK678361 no disease in from the day groups 14, ceived GSK678361 for the entire dura-tion of the study. In contrast, untreated and progress vehicle-treated der-curve with mice continued to 4c (data for 1mg/kg GSK678361 treat-analysis clinical are signs. Area-un-shown in Fig. ment groups not shown).

Importantly, it appears that GSK678361 was associated able to lustrated in Fig. 5, 4 weeks of chronic with reverse chronic joint CIA. destruction As il-CIA in ammation was associated with synovitis, evidenced in the typical sections illus-and bone erosions, as trated and for untreated animals (Fig. Treatment with GSK678361 from day vehicle-treated animals (Fig. 5b). 5a) 1 of arthritis signi cantly (susp<0.001 ver-in ammation vehicle-treated mice) reduced joint and were evident even after 14 days vehi-5f). Changes and destruction in joint pathology (Fig. 5c cle treatment (Fig. 5e), with 30% and 70% joints showing moderate or severe changes respectively (data not shown). Treatment from day 14 of arthritis until the end of the study (day 29) resulted in to those the joints from appearing animals who comparable received

上一页第6页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email